business
Legend Biotech Q1 Earnings Call Highlights
Key takeaways
- Legend Biotech Q1 Earnings Call Highlights Market Beat Tue, May 12, 2026 at 8:07 PM GMT+7 7 min read LEGN Legend Biotech logo Key Points Interested in Legend Biotech Corporation Sponsored ADR?
- CARVYKTI sales surged in Q1 2026, with net trade sales of about $597 million, up 62% year over year.
- Manufacturing execution improved but margins dipped due to one-time ramp costs at expanded facilities.
Legend Biotech Q1 Earnings Call Highlights Market Beat Tue, May 12, 2026 at 8:07 PM GMT+7 7 min read LEGN Legend Biotech logo Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better.
CARVYKTI sales surged in Q1 2026, with net trade sales of about $597 million, up 62% year over year. Growth was driven by earlier-line use in the U.S. and strong international expansion, with ex-U.S. sales rising more than 200%.
Manufacturing execution improved but margins dipped due to one-time ramp costs at expanded facilities. Legend said gross margin was 41% in the quarter and expects it to rebound above 50% in Q2 as utilization improves.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
Earnings call transcript: Carl Zeiss Meditec Q2 2026 highlights adjusted EPS beat
Investing.com
Earnings call transcript: Sunoco LP Q1 2026 earnings beat expectations
Investing.com
Earnings call transcript: Satellogic V reports Q1 2026 revenue surge
Investing.com
Earnings call transcript: 3D Systems Q1 2026 sees significant earnings beat
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop